

Maria Stamelou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7979866/publications.pdf>

Version: 2024-02-01

159
papers

10,762
citations

41344

49
h-index

40979

93
g-index

162
all docs

162
docs citations

162
times ranked

9809
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
2	Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. <i>Movement Disorders</i> , 2018, 33, 75-87.	3.9	918
3	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	3.9	608
4	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	3.7	330
5	The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. <i>Movement Disorders</i> , 2014, 29, 1758-1766.	3.9	286
6	Reward Pays the Cost of Noise Reduction in Motor and Cognitive Control. <i>Current Biology</i> , 2015, 25, 1707-1716.	3.9	272
7	The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. <i>Brain</i> , 2012, 135, 1668-1681.	7.6	246
8	Mutations in ANO3 Cause Dominant Craniocervical Dystonia: Ion Channel Implicated in Pathogenesis. <i>American Journal of Human Genetics</i> , 2012, 91, 1041-1050.	6.2	224
9	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	3.9	222
10	What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 319-323.	1.9	186
11	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	3.9	179
12	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. <i>Brain</i> , 2014, 137, 2480-2492.	7.6	169
13	â€œAtypicalâ€ atypical parkinsonism: New genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophyâ€”A diagnostic guide. <i>Movement Disorders</i> , 2013, 28, 1184-1199.	3.9	167
14	AFQ056 treatment of levodopaâ€-induced dyskinesias: Results of 2 randomized controlled trials. <i>Movement Disorders</i> , 2011, 26, 1243-1250.	3.9	162
15	The phenotypic spectrum of DYT24 due to ANO3 mutations. <i>Movement Disorders</i> , 2014, 29, 928-934.	3.9	161
16	The expanding universe of disorders of the basal ganglia. <i>Lancet</i> , 2014, 384, 523-531.	18.7	155
17	Mutations in HPCA Cause Autosomal-Recessive Primary Isolated Dystonia. <i>American Journal of Human Genetics</i> , 2015, 96, 657-665.	6.2	151
18	The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 650-656.	1.9	141

#	ARTICLE	IF	CITATIONS
19	<i>ADCY5</i> mutations are another cause of benign hereditary chorea. <i>Neurology</i> , 2015, 85, 80-88.	1.1	140
20	Short-term effects of coenzyme Q ₁₀ in progressive supranuclear palsy: A randomized, placebo-controlled trial. <i>Movement Disorders</i> , 2008, 23, 942-949.	3.9	135
21	Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. <i>Movement Disorders</i> , 2016, 31, 1226-1230.	3.9	134
22	Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 48-57.	3.9	134
23	The clinical and genetic heterogeneity of paroxysmal dyskinesias. <i>Brain</i> , 2015, 138, 3567-3580.	7.6	129
24	THAP1 mutations and dystonia phenotypes: Genotype phenotype correlations. <i>Movement Disorders</i> , 2012, 27, 1290-1294.	3.9	126
25	Psychogenic palatal tremor may be underrecognized: Reappraisal of a large series of cases. <i>Movement Disorders</i> , 2012, 27, 1164-1168.	3.9	126
26	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
27	Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. <i>Movement Disorders</i> , 2016, 31, 1506-1517.	3.9	120
28	Dystonia in corticobasal degeneration: A review of the literature on 404 pathologically proven cases. <i>Movement Disorders</i> , 2012, 27, 696-702.	3.9	119
29	HäABC syndrome and DYT4: Variable expressivity or pleiotropy of TUBB4 mutations?. <i>Movement Disorders</i> , 2015, 30, 828-833.	3.9	117
30	Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 151-166.	0.7	105
31	Dystonia with brain manganese accumulation resulting from <i>SLC30A10</i> mutations: A new treatable disorder. <i>Movement Disorders</i> , 2012, 27, 1317-1322.	3.9	104
32	The Clinical Syndrome of Paroxysmal Exercise-Induced Dystonia: Diagnostic Outcomes and an Algorithm. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 57-61.	1.5	100
33	Clinical relevance of serum antibodies to extracellular <i>N</i> -methyl-d-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 708-713.	1.9	97
34	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
35	Rational therapeutic approaches to progressive supranuclear palsy. <i>Brain</i> , 2010, 133, 1578-1590.	7.6	83
36	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018, 33, 21-35.	3.9	79

#	ARTICLE	IF	CITATIONS
37	Movement Disorders on YouTube â€” Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.	27.0	77
38	Psychogenic paroxysmal movement disorders â€” Clinical features and diagnostic clues. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 41-46.	2.2	77
39	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
40	In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: A DTI study using TBSS. <i>Movement Disorders</i> , 2010, 25, 1232-1238.	3.9	70
41	Serotonergic pathology and disease burden in the premotor and motor phase of A53T Î±-synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.	10.2	70
42	Manual MRI morphometry in Parkinsonian syndromes. <i>Movement Disorders</i> , 2017, 32, 778-782.	3.9	67
43	ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 37-43.	2.2	67
44	Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. <i>Neurology</i> , 2013, 81, 1148-1151.	1.1	65
45	Transducer-based evaluation of tremor. <i>Movement Disorders</i> , 2016, 31, 1327-1336.	3.9	64
46	Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study. <i>Movement Disorders</i> , 2014, 29, 1820-1825.	3.9	62
47	The role of cerebellum in patients with late onset cervical/segmental dystonia?â€”Evidence from the clinic. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1317-1322.	2.2	57
48	Health-Related Quality of Life in Multiple System Atrophy and Progressive Supranuclear Palsy. <i>Neurodegenerative Diseases</i> , 2011, 8, 438-446.	1.4	53
49	Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. <i>Movement Disorders</i> , 2015, 30, 1830-1834.	3.9	53
50	Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. <i>Movement Disorders</i> , 2017, 32, 842-852.	3.9	52
51	Atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2013, 26, 401-405.	3.6	49
52	The distinct movement disorder in anti-NMDA receptor encephalitis may be related to status dissociatus: A hypothesis. <i>Movement Disorders</i> , 2012, 27, 1360-1363.	3.9	46
53	Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. <i>Neurology</i> , 2012, 79, 435-441.	1.1	45
54	Magnetic resonance imaging in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2011, 258, 549-558.	3.6	44

#	ARTICLE	IF	CITATIONS
55	Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2012, 6, 88.	2.0	44
56	<i>In vivo</i> Evidence for Cerebral Depletion in High-Energy Phosphates in Progressive Supranuclear Palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 861-870.	4.3	43
57	Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. <i>Movement Disorders</i> , 2014, 29, 245-251.	3.9	43
58	Circulating Brain-Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 457-467.	3.9	43
59	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. <i>Nature Reviews Neurology</i> , 2021, 17, 601-620.	10.1	41
60	Functional movement disorders are not uncommon in the elderly. <i>Movement Disorders</i> , 2013, 28, 540-543.	3.9	40
61	Dystonic opisthotonus: A œered flagœ for neurodegeneration with brain iron accumulation syndromes?. <i>Movement Disorders</i> , 2013, 28, 1325-1329.	3.9	39
62	Pain in Parkinson's Disease: Current Concepts and a New Diagnostic Algorithm. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 357-364.	1.5	39
63	All in the blink of an eye: new insight into cerebellar and brainstem function in <sc>DYT</sc>1 and <sc>DYT</sc>6 dystonia. <i>European Journal of Neurology</i> , 2015, 22, 762-767.	3.3	38
64	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4œRepeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
65	A Review of Treatment Options for Progressive Supranuclear Palsy. <i>CNS Drugs</i> , 2016, 30, 629-636.	5.9	36
66	Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. <i>Neuroscience Letters</i> , 2018, 672, 145-149.	2.1	35
67	Atypical Parkinsonism. <i>Neurologic Clinics</i> , 2015, 33, 39-56.	1.8	34
68	Higher probability of prodromal Parkinson disease is related to lower cognitive performance. <i>Neurology</i> , 2019, 92, e2261-e2272.	1.1	34
69	Familial psychogenic movement disorders. <i>Movement Disorders</i> , 2013, 28, 1295-1298.	3.9	31
70	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <sc>Movement Disorder Society</sc> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.5	31
71	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	3.9	31
72	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 742-747.	3.9	29

#	ARTICLE	IF	CITATIONS
73	Treatment of Focal Dystonia. Current Treatment Options in Neurology, 2012, 14, 213-229.	1.8	28
74	Multiple system atrophy-mimicking conditions: Diagnostic challenges. Parkinsonism and Related Disorders, 2016, 22, S12-S15.	2.2	28
75	Selective cognitive impairment and hyposmia in p.A53T <i>SNCA</i> PD vs typical PD. Neurology, 2018, 90, e864-e869.	1.1	28
76	Tremulous cervical dystonia is likely to be familial: Clinical characteristics of a large cohort. Parkinsonism and Related Disorders, 2013, 19, 634-638.	2.2	27
77	Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. Parkinsonism and Related Disorders, 2017, 35, 82-87.	2.2	27
78	Patients with idiopathic rapidâ€œeyeâ€œmovement sleep behavior disorder show normal gastric motility assessed by the ¹³Câ€œoctanoate breath test. Movement Disorders, 2011, 26, 2559-2563.	3.9	26
79	The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism and Related Disorders, 2015, 21, 1264-1268.	2.2	25
80	The Motor Syndrome of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 25-32.	2.0	23
81	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€œ”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	3.9	22
82	Genotypeâ€œPhenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Movement Disorders, 2021, 36, 1499-1510.	3.9	22
83	Markedly asymmetric presentation in multiple system atrophy. Parkinsonism and Related Disorders, 2013, 19, 901-905.	2.2	21
84	Nonmotor Features in Atypical Parkinsonism. International Review of Neurobiology, 2017, 134, 1285-1301.	2.0	21
85	The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 67, 105-112.	2.2	21
86	Autophagy dysfunction in peripheral blood mononuclear cells of Parkinsonâ€™s disease patients. Neuroscience Letters, 2019, 704, 112-115.	2.1	21
87	Worldwide barriers to genetic testing for movement disorders. European Journal of Neurology, 2021, 28, 1901-1909.	3.3	21
88	Combined 1H and 31P MR spectroscopic imaging: impaired energy metabolism in severe carotid stenosis and changes upon treatment. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2009, 22, 43-52.	2.0	19
89	Clinical pain and experimental pain sensitivity in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2012, 18, 606-608.	2.2	19
90	Progressive supranuclear palsy. International Review of Neurobiology, 2019, 149, 49-86.	2.0	19

#	ARTICLE	IF	CITATIONS
91	Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. <i>Movement Disorders</i> , 2017, 32, 1620-1630.	3.9	18
92	Phenotypic Characteristics in GBA-Associated Parkinson's Disease: A Study in a Greek Population. <i>Journal of Parkinson's Disease</i> , 2018, 8, 101-105.	2.8	18
93	Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation. <i>Journal of Neurology</i> , 2013, 260, 656-660.	3.6	17
94	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	2.2	17
95	Atypical parkinsonism – new advances. <i>Current Opinion in Neurology</i> , 2016, 29, 480-485.	3.6	16
96	Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism. <i>CNS Drugs</i> , 2018, 32, 827-837.	5.9	16
97	Motor function and the probability of prodromal Parkinson's disease in older adults. <i>Movement Disorders</i> , 2019, 34, 1345-1353.	3.9	16
98	Frontotemporal dementia spectrum: first genetic screen in a Greek cohort. <i>Neurobiology of Aging</i> , 2019, 75, 224.e1-224.e8.	3.1	16
99	Frailty and Prodromal Parkinson's Disease: Results From the HELIAD Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 622-629.	3.6	16
100	Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage. <i>European Journal of Pain</i> , 2016, 20, 1223-1228.	2.8	15
101	A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1802-1809.	3.9	15
102	Susceptibility-weighted imaging changes suggesting brain iron accumulation in Huntington's disease: an epiphenomenon which causes diagnostic difficulty. <i>European Journal of Neurology</i> , 2014, 21, e16-7.	3.3	14
103	Interventions in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S93-S95.	2.2	14
104	Nigrostriatal upregulation of 5-HT _{2A} receptors correlates with motor dysfunction in progressive supranuclear palsy. <i>Movement Disorders</i> , 2009, 24, 1170-1175.	3.9	13
105	TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?. <i>Movement Disorders</i> , 2017, 32, 1159-1162.	3.9	13
106	Isolated and combined genetic tremor syndromes: a critical appraisal based on the 2018 MDS criteria. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 121-140.	2.2	13
107	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
108	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016, 23, 772-779.	3.3	12

#	ARTICLE	IF	CITATIONS
127	Levodopaâ€Responsive Parkinsonism with Prominent Freezing and Abnormal <scp>Dopamine Transporter</scp> Scan Associated with <scp>SANDO</scp> Syndrome. Movement Disorders Clinical Practice, 2015, 2, 304-307.	1.5	7
128	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	2.2	7
129	Diseaseâ€Modifying Treatments for Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2015, 2, 3-5.	1.5	6
130	Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study. Parkinsonism and Related Disorders, 2015, 21, 533-535.	2.2	6
131	Emerging drugs for progressive supranuclear palsy. Expert Opinion on Emerging Drugs, 2019, 24, 83-92.	2.4	6
132	REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers. Sleep, 2021, 44, .	1.1	6
133	Childhoodâ€Onset Chorea Caused by a Recurrent De Novo <i>DRD2</i> Variant. Movement Disorders, 2021, 36, 1472-1473.	3.9	6
134	Dietary Inflammatory Index score and prodromal Parkinson's disease incidence: The HELIAD study. Journal of Nutritional Biochemistry, 2022, 105, 108994.	4.2	6
135	Association of the Polygenic Risk Score With the Probability of Prodromal Parkinsonâ€™s Disease in Older Adults. Frontiers in Molecular Neuroscience, 2021, 14, 739571.	2.9	6
136	Tremor in motor neuron disease may be central rather than peripheral in origin. European Journal of Neurology, 2019, 26, 394.	3.3	5
137	DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. Parkinsonism and Related Disorders, 2020, 77, 36-42.	2.2	5
138	Late life psychotic features in prodromal Parkinson's disease. Parkinsonism and Related Disorders, 2021, 86, 67-73.	2.2	5
139	Advances in the Clinical Differential Diagnosis of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 79-127.	2.0	4
140	How to approach a patient with parkinsonism â€“ red flags for atypical parkinsonism. International Review of Neurobiology, 2019, 149, 1-34.	2.0	4
141	Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Movement Disorders, 2011, 26, 901-905.	3.9	3
142	Lateâ€onset cerebellar ataxia: Do not forget Friedreich's. Movement Disorders, 2016, 31, 7-8.	3.9	3
143	Serum Uric Acid in LRRK2 Related Parkinsonâ€™s Disease: Longitudinal Data from the PPMI Study. Journal of Parkinson's Disease, 2021, 11, 633-640.	2.8	3
144	The entity of parkinsonism and associated lipomatosis. Neurology, 2014, 83, 1673-1674.	1.1	2

#	ARTICLE	IF	CITATIONS
145	From a single nucleotide polymorphism to tau pathology: Apoptosin is the missing link. <i>Movement Disorders</i> , 2015, 30, 1871-1872.	3.9	2
146	Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1087-1088.	3.9	2
147	The Discovery of Central Nervous System Lymphatic Vessels: The Missing Link That Closes the Circle of Brain Immunosurveillance. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 29-30.	1.5	1
148	Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: whatâ€™s in a phenotype?. <i>Journal of the Neurological Sciences</i> , 2018, 390, 84-86.	0.6	1
149	A special issue on childhoodâ€”onset movement disorders. <i>Movement Disorders</i> , 2019, 34, 595-597.	3.9	1
150	<sc><i>LRP1</i></sc>: A Novel Mediator of Tau Uptake. <i>Movement Disorders</i> , 2020, 35, 1136-1136.	3.9	1
151	Commentary for â€œSlowing of saccadic eye movements in sporadic Creutzfeldtâ€”Jakob diseaseâ€”, <i>Movement Disorders</i> , 2013, 28, 293-294.	3.9	0
152	LOWER URINARY TRACT SYMPTOMS IN FUNCTIONAL MOVEMENT DISORDERS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.56-e2.	1.9	0
153	Commentary. <i>Movement Disorders</i> , 2014, 29, 310-310.	3.9	0
154	Intrafamilial variability in a polish family harbouring a frameshift THAP1 mutation. <i>Journal of the Neurological Sciences</i> , 2018, 388, 158.	0.6	0
155	Neuroprotection in multiple system atrophy: unresolved issues. <i>Lancet Neurology</i> , The, 2019, 18, 710-711.	10.2	0
156	The â€œzig-zagâ€”sign in progressive supranuclear palsy â€” The slowness of vertical saccades was the clue. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 6-7.	2.2	0
157	Commentary: Insulinomaâ€”induced Hypoglycemia with Generalized Chorea, Dystonia, and Ataxia: A Neurological Kaleidoscope. <i>Movement Disorders Clinical Practice</i> , 2021, 8, S9-S10.	1.5	0
158	The different syndromes in Parkinson's disease: an overview. , 2020, , 235-249.		0
159	Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 72-74.	2.2	0